MICHAEL PAUL PERKINS

Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease SAVANNAH, GA NPI 1659472017

General Payments — all program years on this page

$67,054.61

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 260
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $2,101.94 across 4 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
GlaxoSmithKline, LLC. $1,950.002
ABIOMED $109.931
Pulmonx Corporation $42.011

By program year

Program yearAmountRecords
2018 $885.8362
2019 $1,217.2398
2020 $4,218.1743
2021 $13,587.4126
2022 $27,901.0720
2023 $17,142.967
2024 $2,101.944

Records — PY2024 (4)

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.